Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396161 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01396161 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 64 participants.
The verdict
NCT01396161, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
Interventions
- DRUG PF-05175157 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01396161
The ClinicalTrials.gov registry entry for NCT01396161 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05175157 or Placebo is the first listed.
NCT01396161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01396161 about?
NCT01396161 is a clinical study titled "A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients". The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
What is the current status of trial NCT01396161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2011-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01396161?
The interventions under investigation include: PF-05175157 or Placebo (DRUG).
Who is sponsoring clinical trial NCT01396161?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.